Agenus Inc. (Agenus) is an immuno-oncology (I-O) company. The Company focuses on the discovery and development of therapies that engage the body's immune system to fight cancer. It is developing a I-O portfolio driven by platforms and programs, such as antibody discovery platforms, including Retrocyte Display, SECANT yeast display and phage display technologies designed to produce human antibodies; antibody candidate programs, including checkpoint modulator (CPM) programs; vaccine programs, including Prophage, AutoSynVax and PhosPhoSynVax, and saponin-based vaccine adjuvants, principally QS-21 Stimulon adjuvant (QS-21 Stimulon). The Company's discovery pipeline includes a range of checkpoint modulating (CPM) antibodies. The Company's vaccine platforms include its heat shock protein (HSP)-based Prophage vaccine candidates, and its synthetic vaccine candidates, ASV and PSV.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Biotechnology & Medical Research
- Sub-Industry: Biotechnology
- Symbol: NASDAQ:AGEN
- CUSIP: 00847G70
- Web: www.agenusbio.com
Capitalization:- Market Cap: $408.82 million
- Outstanding Shares: 99,712,000
Average Prices:- 50 Day Moving Avg: $3.84
- 200 Day Moving Avg: $3.85
- 52 Week Range: $3.20 - $7.49
P/E:- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -3.11
- P/E Growth: 0.00
Sales & Book Value:- Annual Revenue: $41.19 million
- Price / Sales: 9.93
- Book Value: ($0.18) per share
- Price / Book: -22.78
Profitability:- EBIDTA: ($92,050,000.00)
- Net Margins: -280.96%
- Return on Equity: -37,577.49%
- Return on Assets: -65.05%
Debt:- Debt-to-Equity Ratio: -7.93%
- Current Ratio: 3.36%
- Quick Ratio: 3.36%
Misc:- Average Volume: 1.11 million shs.
- Beta: 2.1
- Short Ratio: 7.7
Frequently Asked Questions for Agenus (NASDAQ:AGEN)
What is Agenus' stock symbol?
Agenus trades on the NASDAQ under the ticker symbol "AGEN."
How were Agenus' earnings last quarter?
Agenus Inc. (NASDAQ:AGEN) announced its quarterly earnings results on Thursday, August, 3rd. The company reported ($0.32) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.36) by $0.04. The business had revenue of $4.21 million for the quarter, compared to analyst estimates of $6.66 million. Agenus had a negative return on equity of 37,577.49% and a negative net margin of 280.96%. The company's quarterly revenue was down 36.1% on a year-over-year basis. During the same quarter in the prior year, the company earned ($0.33) earnings per share. View Agenus' Earnings History.
When will Agenus make its next earnings announcement?
Where is Agenus' stock going? Where will Agenus' stock price be in 2017?
4 brokerages have issued 12-month price objectives for Agenus' stock. Their predictions range from $5.00 to $7.00. On average, they anticipate Agenus' stock price to reach $6.33 in the next twelve months. View Analyst Ratings for Agenus.
Who are some of Agenus' key competitors?
Some companies that are related to Agenus include Enanta Pharmaceuticals (ENTA), Spectrum Pharmaceuticals (SPPI), Crispr Theraptc (CRSP), ImmunoGen (IMGN), WAVE Life Sciences (WVE), Abeona Therapeutics (ABEO), AC Immune SA (ACIU), ANI Pharmaceuticals (ANIP), Inovio Pharmaceuticals (INO), Celyad SA (CYAD), Kala Pharmaceuticals (KALA), PDL BioPharma (PDLI), Adamas Pharmaceuticals (ADMS), Voyager Therapeutics (VYGR), Mesoblast Limited (MESO), Cara Therapeutics (CARA), Arbutus Biopharma Corporation (ABUS) and Celldex Therapeutics (CLDX).
Who are Agenus' key executives?
Agenus' management team includes the folowing people:
- Garo H. Armen Ph.D., Chairman of the Board, Chief Executive Officer, Founder
- Christine M. Klaskin, Vice President - Finance
- Karen Higgins Valentine, General Counsel, Chief Legal Officer
- Ozer Baysal, Chief Commercial Officer, Head of HR
- Jean-Marie Cuillerot M.D., Chief Medical Officer
- Brian Corvese, Independent Director
- Wadih Jordan, Independent Director
- Shalini Sharp, Independent Director
- Ulf Wiinberg, Independent Director
- Timothy R. Wright, Independent Director
Who owns Agenus stock?
Agenus' stock is owned by a number of of retail and institutional investors. Top institutional investors include Vanguard Group Inc. (3.56%), Artal Group S.A. (2.02%), FMR LLC (1.50%), State Street Corp (1.40%), Northern Trust Corp (0.95%) and Candriam Luxembourg S.C.A. (0.55%). Company insiders that own Agenus stock include Charles Evan Ballantyne, Corp Incyte, Garo H Armen, Ozer Baysal and Ulf Wiinberg. View Institutional Ownership Trends for Agenus.
Who sold Agenus stock? Who is selling Agenus stock?
Agenus' stock was sold by a variety of institutional investors in the last quarter, including State Street Corp, Artal Group S.A., Chicago Equity Partners LLC, Bank of New York Mellon Corp, Virtu KCG Holdings LLC, FMR LLC, California State Teachers Retirement System and Schwab Charles Investment Management Inc.. View Insider Buying and Selling for Agenus.
Who bought Agenus stock? Who is buying Agenus stock?
Agenus' stock was bought by a variety of institutional investors in the last quarter, including Spark Investment Management LLC, Vanguard Group Inc., Captrust Financial Advisors, Wells Fargo & Company MN, State of Wisconsin Investment Board, Northern Trust Corp, OxFORD Asset Management LLP and Alliancebernstein L.P.. Company insiders that have bought Agenus stock in the last two years include Charles Evan Ballantyne, Corp Incyte, Garo H Armen, Ozer Baysal and Ulf Wiinberg. View Insider Buying and Selling for Agenus.
How do I buy Agenus stock?
Shares of Agenus can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Agenus' stock price today?
One share of Agenus stock can currently be purchased for approximately $4.10.
MarketBeat Community Rating for Agenus (NASDAQ AGEN)MarketBeat's community ratings are surveys of what our community members think about Agenus and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Consensus Ratings for Agenus (NASDAQ:AGEN) (How are Consensus Ratings Calculated?) MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
| Ratings Breakdown: | 1 Hold Rating, 3 Buy Ratings |
| Consensus Rating: | Buy (Score: 2.75) |
| Consensus Price Target: | $6.33 (54.47% upside) |
Analysts' Ratings History for Agenus (NASDAQ:AGEN)
Show:
| Date | Firm | Action | Rating | Price Target | Impact on Share Price | Details |
|---|
| 8/4/2017 | Jefferies Group LLC | Reiterated Rating | Buy | $7.00 | High |  |
| 5/6/2017 | HC Wainwright | Set Price Target | Hold | $5.00 | Low | |
| 4/23/2017 | Maxim Group | Reiterated Rating | Buy | $7.00 | Medium | |
| 12/1/2016 | JMP Securities | Reiterated Rating | Buy | | N/A | |
| 3/9/2016 | J P Morgan Chase & Co | Lower Price Target | Market Outperform | $17.00 -> $15.00 | N/A | |
| 12/31/2015 | Oppenheimer Holdings, Inc. | Reiterated Rating | Positive -> Outperform | $14.00 | N/A | |
(Data available from 9/25/2015 forward)
Earnings History for Agenus (NASDAQ:AGEN)Earnings History by Quarter for Agenus (NASDAQ AGEN)| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 10/26/2017 | | | | | | | | |
| 8/3/2017 | Q2 2017 | ($0.36) | ($0.32) | $6.66 million | $4.21 million | View | Listen | |
| 5/4/2017 | Q1 2017 | ($0.32) | ($0.18) | $5.22 million | $26.96 million | View | Listen | |
| 3/9/2017 | Q4 2016 | ($0.30) | ($0.30) | $6.01 million | $5.58 million | View | Listen | |
| 10/27/2016 | Q316 | ($0.32) | ($0.47) | $6.15 million | $4.45 million | View | Listen | |
| 7/28/2016 | Q216 | ($0.34) | ($0.33) | $5.12 million | $6.59 million | View | Listen | |
| 4/28/2016 | Q116 | ($0.23) | ($0.37) | $6.74 million | $5.96 million | View | Listen | |
| 3/3/2016 | Q415 | ($0.17) | ($0.18) | $9.39 million | $7.64 million | View | Listen | |
| 10/27/2015 | Q315 | ($0.15) | ($0.16) | $5.71 million | $6.85 million | View | Listen | |
| 7/23/2015 | Q215 | ($0.15) | ($0.44) | $5.71 million | $6.38 million | View | Listen | |
| 4/23/2015 | Q115 | ($0.15) | ($0.21) | $11.66 million | $3.95 million | View | N/A | |
| 2/26/2015 | Q414 | ($0.15) | ($0.18) | $0.66 million | $1.62 million | View | N/A | |
| 10/31/2014 | Q314 | ($0.15) | ($0.13) | $1.96 million | $1.56 million | View | N/A | |
| 7/24/2014 | Q214 | ($0.11) | ($0.12) | $0.71 million | $3.07 million | View | N/A | |
| 5/8/2014 | Q114 | ($0.16) | $0.01 | $0.55 million | $0.72 million | View | N/A | |
| 3/5/2014 | Q413 | ($0.24) | ($0.16) | $870.00 million | $393.00 million | View | N/A | |
| 10/24/2013 | Q313 | ($0.27) | ($0.24) | | $736.00 million | View | N/A | |
| 7/25/2013 | Q2 2013 | ($0.21) | ($0.40) | | | View | N/A | |
| 2/28/2013 | Q4 2012 | ($0.24) | ($0.23) | $0.72 million | $1.09 million | View | N/A | |
| 7/28/2011 | | ($0.05) | ($0.05) | | | View | N/A | |
(Data available from 1/1/2011 forward)
Earnings Estimates for Agenus (NASDAQ:AGEN)2017 EPS Consensus Estimate: ($1.28)
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|
| Q1 2017 | 2 | ($0.33) | ($0.24) | ($0.29) |
| Q2 2017 | 2 | ($0.34) | ($0.30) | ($0.32) |
| Q3 2017 | 2 | ($0.34) | ($0.31) | ($0.33) |
| Q4 2017 | 1 | ($0.35) | ($0.35) | ($0.35) |
(Data provided by Zacks Investment Research)
Dividend History for Agenus (NASDAQ:AGEN)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Agenus (NASDAQ:AGEN)Insider Ownership Percentage: 7.90%
Institutional Ownership Percentage: 39.51%
Insider Trades by Quarter for Agenus (NASDAQ:AGEN)| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Details |
|---|
| 4/12/2017 | Garo H Armen | CEO | Buy | 100,000 | $3.35 | $335,000.00 | |
| 2/14/2017 | Corp Incyte | Major Shareholder | Buy | 10,000,000 | $6.00 | $60,000,000.00 | |
| 9/6/2016 | Ulf Wiinberg | Director | Buy | 30,000 | $6.29 | $188,700.00 | |
| 5/9/2016 | Garo H Armen | CEO | Buy | 100,000 | $3.18 | $318,000.00 | |
| 5/5/2016 | Ozer Baysal | Insider | Buy | 2,250 | $3.10 | $6,975.00 | |
| 3/7/2016 | Garo H Armen | CEO | Buy | 200,000 | $4.03 | $806,000.00 | |
| 12/29/2015 | Garo H. Armen | CEO | Sell | 219,576 | $4.59 | $1,007,853.84 | |
| 12/28/2015 | Garo H. Armen | CEO | Sell | 134,352 | $4.60 | $618,019.20 | |
| 9/25/2015 | Charles Evan Ballantyne | CFO | Buy | 10,000 | $5.05 | $50,500.00 | |
| 9/25/2015 | Garo H Armen | CEO | Buy | 100,000 | $5.03 | $503,000.00 | |
| 4/29/2015 | Shahzad Malik | Director | Sell | 1,107,377 | $7.11 | $7,873,450.47 | |
| 1/9/2015 | Qvt Associates Gp Llc | Major Shareholder | Sell | 2,343,630 | $5.31 | $12,444,675.30 | |
| 1/23/2014 | Karen Valentine | VP | Sell | 2,850 | $3.50 | $9,975.00 | |
(Data available from 1/1/2013 forward)
Headline Trends for Agenus (NASDAQ:AGEN)
Latest Headlines for Agenus (NASDAQ:AGEN)
| Source: |
|
| Date | Headline |
|---|
 | Agenus Inc. (AGEN) Receives Consensus Rating of "Hold" from Analysts
www.americanbankingnews.com - September 23 at 2:44 AM |
 | Agenus, Inc. breached its 50 day moving average in a Bearish Manner : AGEN-US : September 22, 2017
finance.yahoo.com - September 22 at 2:54 PM |
 | Agenus to Present at Two Healthcare Investor Conferences In September - PR Newswire (press release)
www.prnewswire.com - September 19 at 3:38 PM |
| Agenus to Present at Two Healthcare Investor Conferences In September
finance.yahoo.com - September 19 at 3:38 PM |
| Zacks: Brokerages Expect Agenus Inc. (AGEN) Will Announce Quarterly Sales of $5.37 Million
www.americanbankingnews.com - September 19 at 6:02 AM |
| Arbutus Biopharma Corporation (ABUS) versus Agenus (AGEN) Critical Analysis
www.americanbankingnews.com - September 18 at 2:50 PM |
| Zacks: Brokerages Anticipate Agenus Inc. (AGEN) to Announce -$0.37 Earnings Per Share
www.americanbankingnews.com - September 17 at 4:44 PM |
 | Another 'Picks And Shovels' Nasdaq Stock With Massive Potential
www.nasdaq.com - September 15 at 1:55 AM |
| GSK's Shingrix containing Agenus' QS-21 Stimulon® adjuvant receives Unanimous FDA Advisory Committee ... - PR Newswire (press release)
www.prnewswire.com - September 13 at 9:43 PM |
| Before You Buy Agenus Inc’s (AGEN), You Should Consider This
finance.yahoo.com - September 13 at 4:40 PM |
| FDA Advisory Committee votes unanimously for Shingrix (HZ/su) in the US for prevention of herpes zoster (shingles) in adults ages 50 and over
finance.yahoo.com - September 13 at 4:40 PM |
| 'Impressed' FDA panel unanimously recommends GSK shingles vaccine
finance.yahoo.com - September 13 at 4:40 PM |
| GSK's Shingrix containing Agenus' QS-21 Stimulon® adjuvant receives Unanimous FDA Advisory Committee recommendation for approval
finance.yahoo.com - September 13 at 4:40 PM |
| ETFs with exposure to Agenus, Inc. : September 12, 2017
finance.yahoo.com - September 11 at 9:27 PM |
| Agenus, Inc. breached its 50 day moving average in a Bullish Manner : AGEN-US : September 11, 2017
finance.yahoo.com - September 11 at 4:23 PM |
| Agenus Inc. (AGEN) Upgraded by ValuEngine to "Sell"
www.americanbankingnews.com - September 9 at 11:58 PM |
| Why Is Agenus (AGEN) Down 11.8% Since the Last Earnings Report? - Nasdaq
www.nasdaq.com - September 5 at 9:37 PM |
| Why Is Agenus (AGEN) Down 11.8% Since the Last Earnings Report?
finance.yahoo.com - September 5 at 4:34 PM |
| $5.37 Million in Sales Expected for Agenus Inc. (AGEN) This Quarter
www.americanbankingnews.com - September 1 at 8:42 AM |
| ETFs with exposure to Agenus, Inc. : August 31, 2017
finance.yahoo.com - August 31 at 8:33 PM |
| Zacks: Analysts Expect Agenus Inc. (AGEN) to Announce -$0.36 EPS
www.americanbankingnews.com - August 30 at 4:06 AM |
| Agenus Inc. (AGEN) Given Average Rating of "Hold" by Brokerages
www.americanbankingnews.com - August 29 at 2:34 AM |
| Agenus, Inc. :AGEN-US: Earnings Analysis: Q2, 2017 By the Numbers : August 25, 2017
finance.yahoo.com - August 25 at 5:12 PM |
| Zacks Investment Research Lowers Agenus Inc. (AGEN) to Hold
www.americanbankingnews.com - August 25 at 2:22 PM |
 | 3 Top Biotech Stocks Under $5 - Motley Fool
www.fool.com - August 19 at 3:26 PM |
| 3 Top Biotech Stocks Under $5 - Motley Fool
www.fool.com - August 19 at 3:26 PM |
| Agenus, Inc. – Value Analysis (NASDAQ:AGEN) : August 18, 2017
finance.yahoo.com - August 18 at 8:50 PM |
| Agenus, Inc. breached its 50 day moving average in a Bearish Manner : AGEN-US : August 7, 2017
finance.yahoo.com - August 7 at 4:31 PM |
| Agenus Inc. (NASDAQ:AGEN) Given Buy Rating at Jefferies Group LLC
www.americanbankingnews.com - August 6 at 12:34 AM |
| Here's Why Agenus Inc. Stock Slipped 13.6% in July - Motley Fool
www.fool.com - August 4 at 9:08 PM |
| Edited Transcript of AGEN earnings conference call or presentation 3-Aug-17 3:00pm GMT
finance.yahoo.com - August 4 at 9:08 PM |
| Here's Why Agenus Inc. Stock Slipped 13.6% in July
finance.yahoo.com - August 4 at 9:08 PM |
| Here's Why Agenus Inc. Stock Slipped 13.6% in July
www.fool.com - August 4 at 6:15 PM |
| Agenus (AGEN) Q2 Loss Narrower Than Expected, Revenues Lag
finance.yahoo.com - August 4 at 3:59 PM |
| Agenus Inc. (AGEN) Receives Average Recommendation of "Hold" from Brokerages
www.americanbankingnews.com - August 4 at 7:44 AM |
| Agenus Reports Second Quarter 2017 Financial Results and Provides Corporate Update
finance.yahoo.com - August 3 at 4:40 PM |
 | Form 8-K AGENUS INC For: Aug 03 - StreetInsider.com
www.streetinsider.com - August 3 at 4:40 PM |
| Sucampo (SCMP) Q2 Earnings & Revenues Beat Estimates, Up Y/Y
finance.yahoo.com - August 3 at 4:40 PM |
| Sucampo (SCMP) Q2 Earnings & Revenues Beat Estimates, Up Y/Y
finance.yahoo.com - August 3 at 4:40 PM |
| Agenus (AGEN) Reports Narrower-than-Expected Q2 Loss
finance.yahoo.com - August 3 at 4:40 PM |
| Agenus (AGEN) Reports Narrower-than-Expected Q2 Loss
finance.yahoo.com - August 3 at 4:40 PM |
| Agenus reports 2Q loss
finance.yahoo.com - August 3 at 4:40 PM |
| Agenus reports 2Q loss
finance.yahoo.com - August 3 at 4:40 PM |
| Agenus Inc. (AGEN) Releases Quarterly Earnings Results, Beats Estimates By $0.04 EPS
www.americanbankingnews.com - August 3 at 3:38 PM |
| Agenus to Report Second Quarter 2017 Financial Results on August 3, 2017; Conference Call to Follow - PR Newswire (press release)
www.prnewswire.com - July 27 at 3:48 PM |
| Zacks: Brokerages Expect Agenus Inc. (AGEN) Will Announce Quarterly Sales of $6.49 Million
www.americanbankingnews.com - July 26 at 1:00 PM |
| Is a Beat in Store for Agenus (AGEN) this Earnings Season?
finance.yahoo.com - July 24 at 1:40 PM |
| Brokerages Expect Agenus Inc. (NASDAQ:AGEN) Will Post Earnings of -$0.36 Per Share
www.americanbankingnews.com - July 24 at 12:36 PM |
| Is a Beat in Store for Alexion (ALXN) this Earnings Season?
www.nasdaq.com - July 20 at 4:16 PM |
| uniQure N.V. (QURE) Shows Strength: Stock Moves 9.1% Higher
finance.yahoo.com - July 20 at 4:16 PM |
Agenus (AGEN) Chart for Monday, September, 25, 2017
